pfizer glp 1 Pfizer's Push into GLP‑1 Drugs Signals a New Era in Obesity Treatment — and a Pfizer Phase IIb Data Support

Containing unlisted, dangerous or unknown ingredients

Edited by Professor Boris Zhivotovsky Supplementary information Rights and permissions Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made

Since the above treatments are often used in combination, resulting in a high incidence of adverse effects and the difficulty of avoiding recurrence after stopping the drugs, it is urgent to find a new effective treatment with fewer side effects

The Carnitine Shuttle: Moving long-chain fatty acids in the mitochondria The carnitine shuttle is a three-step transport system that enables long-chain fatty acids to cross the inner mitochondrial membrane for -oxidation